Trial Search Results
Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.
Stanford is currently not accepting patients for this trial.
- Procedure: high dose chemotherapy then autologous hematopoietic cell transplant
Inclusion Criteria:- must be in remission
- adequate organ function
Exclusion Criteria:- prior MDS
- active infection
- liver disease
Ages Eligible for Study
16 Years - 69 Years
Genders Eligible for Study